Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and stabilize IOP. Pharmacotherapy is widely used, although nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease—primary open-angle glaucoma (OAG). Although the European glaucoma therapy market is crowded and highly genericized, branded therapies play an important role in later lines of treatment. The EMA-approved therapies Rhokiinsa and Roclanda could further expand the treatment armamentarium for OAG if they become available in European markets. Nonpharmacological approaches to treating OAG include incisional glaucoma surgery, selective laser trabeculoplasty (SLT), and devices for micro / minimally invasive glaucoma surgery (MIGS).
Questions answered
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: EU5.
Primary research: Survey of 253 EU5 ophthalmologists.
Key drugs covered: Simbrinza, Diamox, Betoptic, Iopidine, latanoprost, brimonidine, timolol, brinzolamide, Rhokiinsa, and Roclanda.
Key companies: Alcon, Santen, Novartis, AbbVie, Pfizer, and Merck & Co.
Key insights provided